View ValuationImeik Technology DevelopmentLtd 향후 성장Future 기준 점검 1/6Imeik Technology DevelopmentLtd (는) 각각 연간 16.3% 및 14.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.7% 로 예상됩니다.핵심 정보16.3%이익 성장률16.26%EPS 성장률Biotechs 이익 성장32.4%매출 성장률14.6%향후 자기자본이익률18.69%애널리스트 커버리지Good마지막 업데이트20 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026공시 • Mar 19Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026, at 14:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China공시 • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026공시 • Nov 15Imeik Technology Development Co.,Ltd. Announces Directorate AppointmentsImeik Technology Development Co.,Ltd. at its EGM held on 13 November 2025 approved appointment of Jian Qing, non-independent director and Chen Zhong, non-independent director.공시 • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025공시 • Aug 21Imeik Technology Development Co.,Ltd. Proposes Interim Dividend for 2025Imeik Technology Development Co.,Ltd. proposed 2025 interim profit distribution plan. Cash dividend/10 shares (tax included): CNY 12.00000000, at the EGM to be held on September 11, 2025.공시 • Jul 02Imeik Technology Development Co.,Ltd. to Report First Half, 2025 Results on Aug 19, 2025Imeik Technology Development Co.,Ltd. announced that they will report first half, 2025 results on Aug 19, 2025공시 • Apr 22Imeik Technology Development Co.,Ltd. Approves Cash Dividend for the Year 2024Imeik Technology Development Co.,Ltd. held its Annual General Meeting of 2024 on 18 April 2025 approved the Cash dividend (tax included) of CNY 38.00000000 per 10 shares for the year 2024.공시 • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025공시 • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China공시 • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥1.54 (vs CN¥1.51 in 3Q 2023)Third quarter 2024 results: EPS: CN¥1.54 (up from CN¥1.51 in 3Q 2023). Revenue: CN¥718.6m (up 1.1% from 3Q 2023). Net income: CN¥464.6m (up 2.1% from 3Q 2023). Profit margin: 65% (in line with 3Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to CN¥212, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥288 per share.Buy Or Sell Opportunity • Oct 11Now 24% undervaluedOver the last 90 days, the stock has risen 25% to CN¥212. The fair value is estimated to be CN¥278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.공시 • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥164, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.Valuation Update With 7 Day Price Move • Aug 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥139, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥277 per share.Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CN¥1.97 (vs CN¥1.82 in 2Q 2023)Second quarter 2024 results: EPS: CN¥1.97 (up from CN¥1.82 in 2Q 2023). Revenue: CN¥848.8m (up 2.3% from 2Q 2023). Net income: CN¥593.5m (up 8.0% from 2Q 2023). Profit margin: 70% (up from 66% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.공시 • Jun 29Imeik Technology Development Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024Imeik Technology Development Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (39% increase in shares outstanding).Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: CN¥2.45 (vs CN¥1.91 in 1Q 2023)First quarter 2024 results: EPS: CN¥2.45 (up from CN¥1.91 in 1Q 2023). Revenue: CN¥808.1m (up 28% from 1Q 2023). Net income: CN¥527.4m (up 27% from 1Q 2023). Profit margin: 65% (in line with 1Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥290, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥489 per share.공시 • Mar 30Imeik Technology Development Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024공시 • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing ChinaReported Earnings • Mar 20Full year 2023 earnings released: EPS: CN¥8.60 (vs CN¥5.84 in FY 2022)Full year 2023 results: EPS: CN¥8.60 (up from CN¥5.84 in FY 2022). Revenue: CN¥2.87b (up 48% from FY 2022). Net income: CN¥1.86b (up 47% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.Buy Or Sell Opportunity • Mar 16Now 20% undervaluedOver the last 90 days, the stock has risen 22% to CN¥340. The fair value is estimated to be CN¥426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 92% in 2 years. Earnings are forecast to grow by 86% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 45% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥410 per share.Buy Or Sell Opportunity • Jan 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥320. The fair value is estimated to be CN¥409, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 87% in the next 2 years.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 47% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥424 per share.공시 • Dec 29Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 20, 2024공시 • Sep 15Imeik Technology Development Co.,Ltd. Approves Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. at its Extraordinary General Meeting of 2023 held on 13 September 2023 approved the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: CN¥2.54 (vs CN¥1.43 in 2Q 2022)Second quarter 2023 results: EPS: CN¥2.54 (up from CN¥1.43 in 2Q 2022). Revenue: CN¥829.4m (up 83% from 2Q 2022). Net income: CN¥549.3m (up 77% from 2Q 2022). Profit margin: 66% (down from 69% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.공시 • Aug 26Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. announced on 25 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.Board Change • Jul 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Renchao Zhang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공시 • Jun 13Imeik Technology Development Co.,Ltd. (SZSE:300896) announces an Equity Buyback for CNY 400 million worth of its shares.Imeik Technology Development Co.,Ltd. (SZSE:300896) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The shares will be repurchased at a price not more than CNY 450 per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans. The program will be valid for a period of 12 months.이익 및 매출 성장 예측XSEC:300896 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20283,5971,8261,4671,9901012/31/20273,1201,6061,5371,7511412/31/20262,6621,3671,1541,543113/31/20262,4231,1461,0801,243N/A12/31/20252,4531,2911,1541,324N/A9/30/20252,5151,4651,2791,465N/A6/30/20252,6681,6261,2051,432N/A3/31/20252,8811,8741,4811,723N/A12/31/20243,0261,9581,6881,927N/A9/30/20243,0752,0261,8622,023N/A6/30/20243,0672,0162,0342,128N/A3/31/20243,0471,9721,9822,064N/A12/31/20232,8691,8581,8901,954N/A9/30/20232,6201,6951,5561,710N/A6/30/20232,5131,6421,4411,609N/A3/31/20232,1381,4041,2171,381N/A1/1/20231,9391,2641,0381,194N/A9/30/20221,9141,2361,1671,220N/A6/30/20221,6991,1181,0281,066N/A3/31/20221,6191,0619991,028N/A1/1/20221,448958920943N/A9/30/20211,268858809839N/A6/30/20211,101718724748N/A3/31/2021889567571589N/A12/31/2020709440394426N/A9/30/2020627376319353N/A12/31/2019558306N/A310N/A12/31/2018321123N/A135N/A12/31/201722282N/A84N/A12/31/201614153N/A55N/A12/31/201511218N/A48N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 300896 의 연간 예상 수익 증가율(16.3%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 300896 의 연간 수익(16.3%)이 CN 시장(27%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 300896 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 300896 의 수익(연간 14.6%)이 CN 시장(연간 16%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 300896 의 수익(연간 14.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 300896의 자본 수익률은 3년 후 18.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 02:40종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Imeik Technology Development Co.,Ltd.는 24명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ethan CuiBofA Global ResearchPei ChengChina Galaxy Securities Co., Ltd.Zhuonan XuChina International Capital Corporation Limited21명의 분석가 더 보기
공시 • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
공시 • Mar 19Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026, at 14:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
공시 • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026
공시 • Nov 15Imeik Technology Development Co.,Ltd. Announces Directorate AppointmentsImeik Technology Development Co.,Ltd. at its EGM held on 13 November 2025 approved appointment of Jian Qing, non-independent director and Chen Zhong, non-independent director.
공시 • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • Aug 21Imeik Technology Development Co.,Ltd. Proposes Interim Dividend for 2025Imeik Technology Development Co.,Ltd. proposed 2025 interim profit distribution plan. Cash dividend/10 shares (tax included): CNY 12.00000000, at the EGM to be held on September 11, 2025.
공시 • Jul 02Imeik Technology Development Co.,Ltd. to Report First Half, 2025 Results on Aug 19, 2025Imeik Technology Development Co.,Ltd. announced that they will report first half, 2025 results on Aug 19, 2025
공시 • Apr 22Imeik Technology Development Co.,Ltd. Approves Cash Dividend for the Year 2024Imeik Technology Development Co.,Ltd. held its Annual General Meeting of 2024 on 18 April 2025 approved the Cash dividend (tax included) of CNY 38.00000000 per 10 shares for the year 2024.
공시 • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
공시 • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
공시 • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥1.54 (vs CN¥1.51 in 3Q 2023)Third quarter 2024 results: EPS: CN¥1.54 (up from CN¥1.51 in 3Q 2023). Revenue: CN¥718.6m (up 1.1% from 3Q 2023). Net income: CN¥464.6m (up 2.1% from 3Q 2023). Profit margin: 65% (in line with 3Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to CN¥212, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥288 per share.
Buy Or Sell Opportunity • Oct 11Now 24% undervaluedOver the last 90 days, the stock has risen 25% to CN¥212. The fair value is estimated to be CN¥278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.
공시 • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥164, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥139, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥277 per share.
Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CN¥1.97 (vs CN¥1.82 in 2Q 2023)Second quarter 2024 results: EPS: CN¥1.97 (up from CN¥1.82 in 2Q 2023). Revenue: CN¥848.8m (up 2.3% from 2Q 2023). Net income: CN¥593.5m (up 8.0% from 2Q 2023). Profit margin: 70% (up from 66% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
공시 • Jun 29Imeik Technology Development Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024Imeik Technology Development Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024
New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (39% increase in shares outstanding).
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: CN¥2.45 (vs CN¥1.91 in 1Q 2023)First quarter 2024 results: EPS: CN¥2.45 (up from CN¥1.91 in 1Q 2023). Revenue: CN¥808.1m (up 28% from 1Q 2023). Net income: CN¥527.4m (up 27% from 1Q 2023). Profit margin: 65% (in line with 1Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥290, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥489 per share.
공시 • Mar 30Imeik Technology Development Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024
공시 • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
Reported Earnings • Mar 20Full year 2023 earnings released: EPS: CN¥8.60 (vs CN¥5.84 in FY 2022)Full year 2023 results: EPS: CN¥8.60 (up from CN¥5.84 in FY 2022). Revenue: CN¥2.87b (up 48% from FY 2022). Net income: CN¥1.86b (up 47% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.
Buy Or Sell Opportunity • Mar 16Now 20% undervaluedOver the last 90 days, the stock has risen 22% to CN¥340. The fair value is estimated to be CN¥426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 92% in 2 years. Earnings are forecast to grow by 86% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 45% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥410 per share.
Buy Or Sell Opportunity • Jan 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥320. The fair value is estimated to be CN¥409, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 87% in the next 2 years.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 47% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥424 per share.
공시 • Dec 29Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 20, 2024
공시 • Sep 15Imeik Technology Development Co.,Ltd. Approves Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. at its Extraordinary General Meeting of 2023 held on 13 September 2023 approved the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.
Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: CN¥2.54 (vs CN¥1.43 in 2Q 2022)Second quarter 2023 results: EPS: CN¥2.54 (up from CN¥1.43 in 2Q 2022). Revenue: CN¥829.4m (up 83% from 2Q 2022). Net income: CN¥549.3m (up 77% from 2Q 2022). Profit margin: 66% (down from 69% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.
공시 • Aug 26Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. announced on 25 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.
Board Change • Jul 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Renchao Zhang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공시 • Jun 13Imeik Technology Development Co.,Ltd. (SZSE:300896) announces an Equity Buyback for CNY 400 million worth of its shares.Imeik Technology Development Co.,Ltd. (SZSE:300896) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The shares will be repurchased at a price not more than CNY 450 per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans. The program will be valid for a period of 12 months.